MedTrace Logo

Improving Hepatitis C Treatment in Injection Drug Users

NCT00148031 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2013-04-24

No results posted yet for this study

Summary

The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.

Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.

Conditions

Interventions

DRUG

Pegylated Interferon and Ribavirin

Both groups with receive the same medical intervention but offered at different locations

BEHAVIORAL

Psychosocial

Assessment of the likelihood of HCV treatment initiation and completion

BEHAVIORAL

On-site (MMT Clinic) HCV evaluation and treatment

Standard HCV treatment with Pegylated Interferon and Ribavirin

BEHAVIORAL

Off-site HCV evaluation and treatment

Standard HCV treatment with Pegylated Interferon and Ribavirin

Sponsors & Collaborators

  • State University of New York - Upstate Medical University

    lead OTHER

Principal Investigators

  • Steven L Batki, MD · State University of New York, Upstate Medical University - Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148031 on ClinicalTrials.gov